The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
The Bronchiectasis Severity Index. An International Derivation and Validation Study
Open accessAbstract
Rationale: There are no risk stratification tools for morbidity and mortality in bronchiectasis. Identifying patients at risk of exacerbations, hospital admissions, and mortality is vital for future research. Objectives: This study describes the derivation and validation of the Bronchiectasis Severity Index (BSI). Methods: Derivation of the BSI used data from a prospective cohort study (Edinburgh, UK, 2008–2012) enrolling 608 patients. Cox proportional hazard regression was used to identify independent predictors of mortality and hospitalization over 4-year follow-up. The score was validated in independent cohorts from Dundee, UK (n = 218); Leuven, Belgium (n = 253); Monza, Italy (n = 105); and Newcastle, UK (n = 126). Measurements and Main Results: Independent predictors of future hospitalization were prior hospital admissions, Medical Research Council dyspnea score greater than or equal to 4, FEV1 < 30% predicted, Pseudomonas aeruginosa colonization, colonization with other pathogenic organisms, and three or more lobes involved on high-resolution computed tomography. Independent predictors of mortality were older age, low FEV1, lower body mass index, prior hospitalization, and three or more exacerbations in the year before the study. The derived BSI predicted mortality and hospitalization: area under the receiver operator characteristic curve (AUC) 0.80 (95% confidence interval, 0.74–0.86) for mortality and AUC 0.88 (95% confidence interval, 0.84–0.91) for hospitalization, respectively. There was a clear difference in exacerbation frequency and quality of life using the St. George’s Respiratory Questionnaire between patients classified as low, intermediate, and high risk by the score (P < 0.0001 for all comparisons). In the validation cohorts, the AUC for mortality ranged from 0.81 to 0.84 and for hospitalization from 0.80 to 0.88. Conclusions: The BSI is a useful clinical predictive tool that identifies patients at risk of future mortality, hospitalization, and exacerbations across healthcare systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Determining transplant timing is difficult due to the wide range of etiologies and demographics. Two non-CF bronchiectasis severity assessment tools were developed from the overall population (not limited to those with advanced lung disease): the FACED score [FEV1, Age, Chronic Pseudomonas aeruginosa, Extension to 1–2 lobes, Dyspnea by modified Medical Research Council scale] and the bronchiectasis severity index (BSI), which adds BMI and exacerbation frequency.”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [273]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two non-CF bronchiectasis severity assessment tools were developed from the overall population (not limited to those with advanced lung disease): the FACED score [FEV1, Age, Chronic Pseudomonas aeruginosa, Extension to 1–2 lobes, Dyspnea by modified Medical Research Council scale] and the bronchiectasis severity index (BSI), which adds BMI and exacerbation frequency.(272, 273)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [273]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to CF, FEV1% predicted has been shown to be discriminating for mortality.”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [273]
The cited source says what the claim attributes to it.
In the citing paper
“One study demonstrated a 4-year mortality of 39% in non-CF bronchiectasis patients with FEV1 < 30% predicted.(273)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [273]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A high FACED score (5–7) has been associated with median survival of approximately 5.5 years.”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [273]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
British Thoracic Society guideline for non-CFbronchiectasis
Pasteur, M. C., Bilton, D., Hill, A. T., & on behalf of the British Thoracic Society Bronchiectasis (non-CF) Guideline Group (2010) · Thorax · doi:10.1136/thx.2010.136119 · Cited by 1,046
Self-citationCystic fibrosis: scoring system with thin-section CT.
Bhalla, M., Turcios, N., Aponte, V, Jenkins, M., Leitman, B. S., McCauley, D. I., & Naidich, D. P. (1991) · Radiology · doi:10.1148/radiology.179.3.2027992 · Cited by 726 · cited 1×
“This score has been widely used in studies of non-CF bronchiectasis but takes into account far fewer variables than scoring systems used in CF, such as the Bhalla score (30).”
MethodLee, T. W. R., Brownlee, K. G., Conway, S. P., Denton, M., & Littlewood, J. M. (2003) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(02)00141-8 · Cited by 713 · cited 1×
“Chronic colonization was defined by the isolation of potentially pathogenic bacteria in sputum culture on two or more occasions, at least 3 months apart in a 1-year period (14, 16, 17).”
An Investigation into Causative Factors in Patients with Bronchiectasis
PASTEUR, M. C., HELLIWELL, S. M., HOUGHTON, S. J., WEBB, S. C., FOWERAKER, J. E., COULDEN, R. A., FLOWER, C. D., BILTON, D., & KEOGAN, M. T. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.4.9906120 · Cited by 684 · cited 2×
“Only four patients in the derivation study were excluded due to NTM, as this is an infrequent underlying cause in UK centers (16, 28).”
BackgroundWong, C., Jayaram, L., Karalus, N., Eaton, T., Tong, C., Hockey, H., Milne, D., Fergusson, W., Tuffery, C., Sexton, P., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60953-2 · Cited by 600
Altenburg, J., de Graaff, C. S., Stienstra, Y., Sloos, J. H., van Haren, E. H. J., Koppers, R. J. H., van der Werf, T. S., & Boersma, W. G. (2013) · JAMA · doi:10.1001/jama.2013.1937 · Cited by 518 · cited 1×
“Macrolide use is associated with a significant increase in adverse events, with 40% of macrolide-treated patients experiencing gastrointestinal side effects in the BAT trial (11).”
BackgroundAscertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis
du Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Raghu, G., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1790oc · Cited by 424
Serisier, D. J., Martin, M. L., McGuckin, M. A., Lourie, R., Chen, A. C., Brain, B., Biga, S., Schlebusch, S., Dash, P., & Bowler, S. D. (2013) · JAMA · doi:10.1001/jama.2013.2290 · Cited by 420
Mortality in bronchiectasis: a long-term study assessing the factors influencing survival
Loebinger, M. R., Wells, A. U., Hansell, D. M., Chinyanganya, N., Devaraj, A., Meister, M., & Wilson, R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00003709 · Cited by 414 · cited 1×
“George’s respiratory questionnaire, all of which support the findings of the present study (26).”
ResultChalmers, J. D., Smith, M. P., McHugh, B. J., Doherty, C., Govan, J. R., & Hill, A. T. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0487oc · Cited by 410 · cited 2×
“Bacteriology All bacteriology was performed on spontaneous early-morning sputum samples as previously described (2).”
BackgroundMethodSelf-citation
Cited by
European Respiratory Society guidelines for the management of adult bronchiectasis
Polverino, E., Goeminne, P. C., McDonnell, M. J., Aliberti, S., Marshall, S. E., Loebinger, M. R., Murris, M., Cantón, R., Torres, A., Dimakou, K., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00629-2017 · Cited by 1,333
Self-citationLeard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
British Thoracic Society Guideline for bronchiectasis in adults
T Hill, A., L Sullivan, A., D Chalmers, J., De Soyza, A., Stuart Elborn, J., Andres Floto, R., Grillo, L., Gruffydd-Jones, K., Harvey, A., S Haworth, C., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212463 · Cited by 617
“The availability of the two clinical scoring systems, the Bronchiectasis Severity Index (BSI) (table 4) [120] and FACED [119] (see Tables 4 and 5), has increased our ability to predict future mortality in patients with bronchiectasis.”
BackgroundMethodInfluentialSelf-citationAdvances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity
Flume, P. A., Chalmers, J. D., & Olivier, K. N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31767-7 · Cited by 545
Self-citationLung microbiome: new insights into the pathogenesis of respiratory diseases
Li, R., Li, J., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01722-y · Cited by 434
“264,265 Although studies are more limited than those on bacteria, fungi, and viruses have also been proven to be involved in the process of bronchiectasis.”
Background
Metadata
- Authors
- Chalmers, J. D., Goeminne, P., Aliberti, S., McDonnell, M. J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L. J., Fardon, T. C., De Soyza, A., & Hill, A. T.
- Affiliations
- University of Dundee (GB)
- Universitair Ziekenhuis Leuven (BE)
- University of Milano-Bicocca (IT)
- Freeman Hospital (GB)
- Adult Bronchiectasis Service and Sir William Leech Centre for Lung Research, Freeman Hospital, Newcastle upon Tyne Hospitals, Heaton, Newcastle, United Kingdom
- Edinburgh Royal Infirmary (GB)
- Corresponding author
- Chalmers, James D.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-01
- Volume
- 189
- Issue
- 5
- Pages
- 576-585
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC3977711
- OpenAlex
- W1992873661
- Semantic Scholar
- 1a48d4179b1f51a15cf0867ff9b732d1d65d75fb
- Cited by
- 1,093
- References
- 31
- Citations by year
- 2026: 94 · 2025: 94 · 2024: 142 · 2023: 75 · 2022: 96 · 2021: 97 · 2020: 101 · 2019: 75 · 2018: 100 · 2017: 96 · 2016: 57 · 2015: 45 · 2014: 18
- FWCI
- 57.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Wellcome Trust
- Health Research Board
- Medical Research Council (MR/L011263/1)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Keywords
- Bronchiectasis Severity Index, bronchiectasis, risk stratification, mortality prediction, hospitalization prediction, exacerbations, Pseudomonas aeruginosa colonization, dyspnea, FEV1, St George's Respiratory Questionnaire, quality of life
- MeSH terms
- Adult, Aged, Aged, 80 and over, Bronchiectasis, Decision Support Techniques, Exercise Test, Female, Follow-Up Studies, Hospitalization, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Surveys and Questionnaires, Respiratory Function Tests, Risk Factors, Severity of Illness Index, Proportional Hazards Models, Disease Progression, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Bronchiectasis Severity Index. An International Derivation and Validation Study. https://app.cochat.ai/papers/10.1164/rccm.201309-1575oc
- The paper
- Chalmers, J. D., Goeminne, P., Aliberti, S., McDonnell, M. J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L. J., Fardon, T. C., De Soyza, A., & Hill, A. T. (2014). The Bronchiectasis Severity Index. An International Derivation and Validation Study. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201309-1575oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.